EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas

Histopathology

Volumn 63, Issue 2, 2013, Pages 271-278

  Rössle, Matthias ^a   Weber, Claudia S ^a   Züllig, Lena ^a   Graf, Nicole ^a   Jochum, Wolfram ^b   Stöckli, Sandro J ^c   Moch, Holger ^a   Huber, Gerhard F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Institute of Pathology   (Switzerland)

^c NONE   (Switzerland)

Author keywords

EGFR; Fluorescence in situ hybridization; Head and neck squamous cell carcinoma; Immunohistochemistry; Oral cavity; Oropharynx; Silver in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; SILVER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CHROMOSOME 7; EARLY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CAVITY; MOUTH SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84880732365     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12175     Document Type: Article

References (49)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. Cancer J. Clin. 1999; 49; 8-31.
2. Grandi C, Alloisio M, Moglia D et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg. 1985; 8; 67-73.
3. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Physics 2004; 59; S21-S26.
4. Bronte G, Terrasi M, Rizzo S et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci. (Elite Ed.) 2011; 3; 879-887.
5. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006; 354; 567-578.
6. Numico G, Silvestris N, Grazioso Russi E. Advances in EGFR-directed therapy in head and neck cancer. Front. Biosci. (Schol. Ed.) 2011; 3; 454-466.
7. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 2006; 42; 109-111.
8. Sheikh Ali MA, Gunduz M, Nagatsuka H et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 2008; 99; 1589-1594.
9. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006; 24; 4170-4176.
10. Cao X, Hao J, Yang X et al. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med. Oncol. 2012; 29; 263-271.
11. Chrysovergis A, Gorgoulis V, Giotakis I et al. Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis. Med. Oncol. 2011; 28; 871-877.
12. Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 2012; 100; 156-163.
13. Laimer K, Spizzo G, Gastl G et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol. 2007; 43; 193-198.
14. Marioni G, Blandamura S, Loreggian L et al. Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression. Eur. Arch. Otorhinolaryngol. 2011; 268; 1779-1787.
15. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Warnakulasuriya S, Forteza J, Fraga M. Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma. J. Oral Pathol. Med. 2012; 41; 559-567.
16. Nakata Y, Uzawa N, Takahashi K et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur. J. Cancer 2011; 47; 2364-2372.
17. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010; 2; 13.
18. Won HS, Jung CK, Chun SH et al. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012; 48; 985-990.
19. Fischer C, Zlobec I, Stockli E et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Hum. Pathol. 2008; 39; 1527-1534.
20. Hong A, Dobbins T, Lee CS et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur. J. Cancer 2010; 46; 2088-2096.
21. Michikawa C, Uzawa N, Sato H, Ohyama Y, Okada N, Amagasa T. Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer. Br. J. Cancer 2011; 104; 850-855.
22. Thomas L, Moore EJ, McGree ME et al. Prognostic features, human papillomavirus status, and epidermal growth factor receptor expression in oral squamous cell carcinoma in young adults. Am. J. Otolaryngol. 2012; 33; 650-655.
23. Ryott M, Wangsa D, Heselmeyer-Haddad K et al. EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur. J. Cancer 2009; 45; 1700-1708.
24. Wheeler S, Siwak DR, Chai R et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin. Cancer Res. 2012; 18; 2278-2289.
25. Licitra L, Mesia R, Rivera F et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 2011; 22; 1078-1087.
26. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J. Clin. Pathol. 2009; 62; 314-324.
27. Dietel M, Ellis I, Höfler H et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007; 451; 19-25.
28. Huang SF, Cheng SD, Chien HT et al. Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol. 2012; 48; 67-72.
29. Freier K, Joos S, Flechtenmacher C et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003; 63; 1179-1182.
30. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 2008; 100; 407-420.
31. Jordan RC, Lingen MW, Perez-Ordonez B et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am. J. Surg. Pathol. 2012; 36; 945-954.
32. Stoeckli SJ. Sentinel node biopsy for oral and oropharyngeal squamous cell carcinoma of the head and neck. Laryngoscope 2007; 117; 1539-1551.
33. Huber G, Zullig L, Soltermann A et al. Down regulation of E-cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 2011; 11; 217.
34. Huber GF, Fritzsche FR, Züllig L et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int. J. Cancer 2011; 129; 1404-1409.
35. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
36. Varella-Garcia M, Diebold J, Eberhard DA et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 2009; 62; 970-977.
37. Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Am. J. Surg. Pathol. 2010; 34; 1180-1185.
38. Wulf M-A, Bode B, Zimmermann D et al. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer. Am. J. Surg. Pathol. 2012; 36; 1801-1808.
39. Perrone F, Suardi S, Pastore E et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2006; 12; 6643-6651.
40. Young RJ, Rischin D, Fisher R et al. Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev. 2011; 20; 1230-1237.
41. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn. Pathol. 2008; 3; 41.
42. Braun M, Stomper J, Boehm D et al. Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization. J. Mol. Diagn. 2012; 14; 322-327.
43. Kim S-H, Koo B-S, Kang S et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int. J. Cancer 2007; 120; 1418-1425.
44. Rena O, Boldorini LR, Gaudino E, Casadio C. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J. Surg. Oncol. 2011; 104; 701-705.
45. Theurillat J-P, Zürrer-Härdi U, Varga Z et al. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol. Immunother. 2007; 56; 1723-1731.
46. Minner S, Rump D, Tennstedt P et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2012; 118; 1268-1275.
47. Martín-Ezquerra G, Salgado R, Toll A et al. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. Br. J. Dermatol. 2010; 163; 1028-1035.
48. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004; 64; 9139-9143.
49. Morris LGT, Taylor BS, Bivona TG et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc. Natl Acad. Sci. USA 2011; 108; 19024-19029.